Ivermectin for Post Exposure Prophylaxis of Covid-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-16

Study Completion Date

2022-10-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Post exposure prophylaxis of healthy contacts is among the measures used for outbreak control of several infectious diseases (e.g., pandemic influenza). No agent is known to be effective in preventing COVID-19, but Ivermectin is one of the drugs that have shown antiviral activity against SARS-CoV-2 in the laboratory. This study aims to evaluate the effect of post exposure prophylaxis with Ivermectin after exposure to COVID-19 among the asymptomatic close contacts.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ivermectin Treatment Efficacy in Covid-19 High Risk Patients

NCT04920942

COVID-19

COMPLETED PHASE3

Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19

NCT04429711

COVID-19

UNKNOWN NA

Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients

NCT05155527

COVID-19

UNKNOWN PHASE2

Efficacy of Ivermectin in COVID-19

NCT04392713

COVID

UNKNOWN NA

Outpatient Use of Ivermectin in COVID-19

NCT04530474

Covid19

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective:

To assess the efficacy of Ivermectin as post exposure prophylaxis in asymptomatic adults (≥18 years of age) who had close-contact exposure to a confirmed case of COVID-19 patient

Secondary Objectives:

1. To compare the viral load (using CT value reading) among close contacts who become positive COVID-19 during follow up period between the Ivermectin and placebo group
2. To assess the adverse effects of Ivermectin within 7 days after each dose

Study Population and Sampel Size Asymptomatic adults (≥18 years of age) who had recent history (less than 5 days) of close contact exposure to a confirmed COVID-19 positive patient as per the definition by CDC.

In this study, the study teams decide to recruit 150 subjects per group, a total of 300 subjects; 30 subjects in each site (15 Ivermectins, 15 placebos)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, double blind, placebo controlled clinical trial

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

This is a randomized, double blind, placebo controlled clinical trial evaluating the effect of Ivermectin for post exposure prophylaxis among close contacts of COVID-19 positive case patient as an index case.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group:

Ivermectin 0.4 mg/kg/day (maximum 24 mg)

Group Type ACTIVE_COMPARATOR

Ivermectin

Intervention Type DRUG

0.4 mg/kg/day-maximum dose is 24 mg.

Control group

Placebo-inactive substance

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Similar to drug in term of tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivermectin

0.4 mg/kg/day-maximum dose is 24 mg.

Intervention Type DRUG

Placebo

Similar to drug in term of tablets

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Asymptomatic individuals exposed to a confirmed positive COVID-19 case within 5 days from the study recruitment day (include household, workplace and social close contact)
2. Aged ≥18 years; male or female
3. No fever with temperature less than 37.5ºC
4. RTK Ag for COVID-19 is negative on the recruitment day.
5. For subject who had received COVID-19 vaccination:

* Any primary series vaccine (eg: Pfizer, Sinovac, AstraZeneca etc) : past 90 days after the second dose
* Any booster vaccine: past 90 days after the booster dose
6. In women of childbearing potential (18-55 years old), negative pregnancy test and agree to use any contraceptive method up to 7 days after the second dose of IP administration
7. Have access to video and phone call
8. Willing to take 2 doses of study medication (2 days apart between Dose 1 and Dose 2)
9. Willing to comply with all study procedures
10. Able to provide written informed consent

Exclusion Criteria

1. Unable to take drugs by mouth
2. History of positive confirmed COVID-19 infection within past 3 months
3. Involved in any COVID-19 vaccine clinical trial
4. Patients with suspected concomitant bacterial, fungal infections, concurrent congestive heart failure prior to initiation of study drug
5. Known case of liver disease (any severity)
6. Alcohol intake more than recommended (2 drinks or more in a day for men and 1 drink or more in a day for women)
7. Mal-absorption syndrome or other clinically significant gastrointestinal disease that may affect absorption of the study drug (non-correctable vomiting, diarrhea, ulcerative colitis, and others).
8. Pregnant or nursing/breastfeeding women or women planning for pregnancy.
9. Female patients who cannot consent to contraceptive use (any method) from the start of IP administration to 7 days after the second dose of IP administration
10. Male patients whose partner cannot agree to use the contraception method as in 9)
11. Patients with a history of gout or on treatment for gout or hyperuricemia
12. Patients receiving immunosuppressant
13. Patients who have previously received Ivermectin.
14. Patients who are not able to provide written consent.
15. Other patients judged ineligible by the principal investigator or sub-investigator

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No